Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care
- The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer
Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers’ scale with GRAIL’s innovative cancer screening technology to dramatically increase access to proactive care.
More than one in three people will develop cancer in their lifetime2, but many cancers can go undetected for longer than necessary especially before symptoms arise. While recommended screenings can catch breast, cervical, colorectal, prostate, and lung cancers early, other aggressive cancers, like pancreatic and ovarian, are often discovered at later stages when treatment is harder and outcomes may be worse. With advances like Galleri® that make cancer screening more accessible, this doesn’t need to be the case.
The Hims & Hers Multi-Cancer Test by Galleri® looks for a shared signal of 50+ types of cancer, including those without recommended screenings. In addition to recommended screenings, this simple blood test can be taken annually and enables customers to proactively screen for cancers that can develop even before symptoms.
Even though cancer screening technology has advanced significantly, there are still too many life-changing diagnoses that should have been made earlier. Access to innovation is the key to changing that,” said Andrew Dudum, co-founder and CEO at Hims & Hers. “World-class care should be available to everyone, not just those with the time and resources to navigate the traditional system. Our platform brings together the best the healthcare industry has to offer in order to close the access gap, and our work with GRAIL is a critical part of delivering cutting-edge care to everyone.”
Galleri’s cutting-edge technology powers early detection of cancer signals in blood, including a prediction of where in the body the signal is likely coming from. The Galleri test does not detect all cancers, and false positive and false negative results can occur.
Hims & Hers is at the forefront of making healthcare more attainable and impactful for those who want to take control of their health,” said Josh Ofman, MD, MSHS, President at GRAIL. “GRAIL believes making validated MCED tests available as a complement to recommended cancer screenings can help to increase cancer detection before cancers spread, improve outcomes, and enable this breakthrough technology to be available to more people. As a leader in digital health solutions, Hims is a natural partner to offer the Galleri test helping bring personalized, innovative healthcare to a broader population.”
We know that cancers found early, before they’ve spread, can potentially have better outcomes than those caught later after the cancer has spread,” said Dr. Pat Carroll, Chief Medical Officer at Hims & Hers. “With access to this new, innovative screening technology, we’re empowering customers to tackle health challenges when treatment can be more manageable and more successful. This is a meaningful step toward helping people live happier, healthier lives.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results.
Source link: https://www.businesswire.com/
